

DRUG PRIOR AUTHORIZATION COMMITTEE

March 21, 2013
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver

Old Business

11:20 – 11:30	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
---------------	--	---------------

New Business

11:30 – 11:45	B. Proposed Actions- New Drug/Product Reviews (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Products iv. Prior Authorization <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver
11:45 – 1:00	C. Preferred Drug List (PDL) i. Benzoyl Peroxide/Clindamycin Topical Agents <ul style="list-style-type: none">• Discussion• Public Hearing• Decision ii. Beta-Adrenergic Agents: Long Acting <ul style="list-style-type: none">• Discussion• Public Hearing• Decision iii. Beta-Adrenergic Agents: Nebulized <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

- iv. **Beta-Adrenergic Agents: Short Acting**
 - Discussion
 - Public Hearing
 - Decision
- v. **COPD Anticholinergics**
 - Discussion
 - Public Hearing
 - Decision
- vi. **Herpes Antivirals**
 - Discussion
 - Public Hearing
 - Decision
- vii. **Inhaled Antibiotics**
 - Discussion
 - Public Hearing
 - Decision
- viii. **Inhaled Corticosteroids**
 - Discussion
 - Public Hearing
 - Decision
- ix. **Intranasal Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- x. **Leukotriene Modifiers**
 - Discussion
 - Public Hearing
 - Decision
- xi. **Low Sedating Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xii. **Low Sedating Antihistamine/Decongestant Combinations**
 - Discussion
 - Public Hearing
 - Decision
- xiii. **Nasal Steroids**
 - Discussion
 - Public Hearing
 - Decision
- xiv. **Onychomycosis Antifungals**
 - Discussion
 - Public Hearing
 - Decision

- xv. **Ophthalmic Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xvi. **Ophthalmic Mast Cell Stabilizers**
 - Discussion
 - Public Hearing
 - Decision
- xvii. **Ophthalmic NSAIDs**
 - Discussion
 - Public Hearing
 - Decision
- xviii. **Ophthalmic Prostaglandin Agonists**
 - Discussion
 - Public Hearing
 - Decision
- xix. **Ophthalmic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xx. **Otic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xxi. **Pancreatic Enzymes**
 - Discussion
 - Public Hearing
 - Decision
- xxii. **Self-Injectable Epinephrine Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxiii. **Topical Agents for Psoriasis**
 - Discussion
 - Public Hearing
 - Decision
- xxiv. **Topical Androgenic Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxv. **Topical Immunomodulators**
 - Discussion
 - Public Hearing
 - Decision

- xxvi. **Topical Retinoids**
 - Discussion
 - Public Hearing
 - Decision
- xxvii. **Topical Steroids**
 - Discussion
 - Public Hearing
 - Decision
- xxviii. **Ulcerative Colitis Agents – Oral**
 - Discussion
 - Public Hearing
 - Decision
- xxix. **Ulcerative Colitis Agents –Rectal**
 - Discussion
 - Public Hearing
 - Decision

D. Preferred Drug List

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30 **Program Utilization Information-Xerox Update** Rhonda Driver/
Jennifer Kemp-Cornelius

1:30-1:50 **Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

Executive Session

1:50-1:55 Minutes Review Discussion/Approval

1:55-2:30 Case Reviews Jenna Twehus

NEXT MEETING: June 20, 2013